Patient preferences for treatment of metastatic melanoma.

To investigate patient preferences for clinical attributes of first-line metastatic melanoma treatments. A discrete-choice experiment and best-worst scaling exercise were used to assess relative preferences for treatment attributes. The 200 survey respondents had distinct preferences. Avoiding a 30% risk of colitis or hormone gland problems and avoiding severe fever were more important to respondents than avoiding a 20% risk of extreme sun sensitivity (p < 0.05). Patients preferred taking pills to receiving intravenous infusions in a clinic. When attributes were combined, approximately 85% of respondents preferred a risk profile similar to targeted therapy over a profile similar to immunotherapy, holding efficacy constant. Taking patient preferences into account can help patients get the full benefit from metastatic melanoma therapies.